CXCL13 and neoplasm: MP2 lysate-pulsed 1st and 2nd Gen DCs significantly reduced tumor burden compared to untreated or UTD DC-treated mice, highlighting the capacity of antigen-loaded DCs engineered to overexpress CD93, CD40L, and CXCL13 to drive robust anti-tumor immunity in the Hu-BLT model.